Uploaded and Shared in Youtube by: MultiVuVideos A new analysis reaffirms that Lexiscan® (regadenoson) Injection, the first selective A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress, requires infrequent use of the drug aminophylline to reverse its effect in the case of adverse events. The low use of aminophylline demonstrates that Lexiscan is similar to the current standard, Adenoscan (adenosine injection). Results were presented today at the 14th Annual Scientific Sessions of the American Society of Nuclear Cardiology (ASNC) in Minneapolis, Minnesota. To view Multimedia News Release go to http://www2.prnewswire.com/mnr/lexiscan/40233/
WHAT IS SYMPOSIER?
Symposier.com is the technological platform that will allow you (and your colleagues) to share medical information, event calendars, clinical cases, new procedures and much more with medicine professionals around the world.
Get in touch with medical professionals around the world and seize the collective experiences and knowledge to the benefit of your own patients.
Establish common-interest groups to build a collaboration network
Learn, comment and publish about local or international medical events
Seize and publish to our video, image and medical documents library
Symposier uploaded this video.
Lexiscan Mechanism of Action
Date: 06 Jan 2010
Uploader: Symposier
Lenght: 6m 30s
Specialty:
Cardiology
Pharmacology
